Melanoma Research Alliance
10
2
2
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
30.0%
3 terminated/withdrawn out of 10 trials
62.5%
-24.0% vs industry average
10%
1 trials in Phase 3/4
40%
2 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Role: collaborator
Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors
Role: collaborator
Wearable Device Intervention to Improve Sun Behaviors in Melanoma Survivors
Role: collaborator
Intermittent Selumetinib for Uveal Melanoma
Role: collaborator
A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence
Role: collaborator
Treatment of Advanced Melanoma With MK-3475 and Peginterferon
Role: collaborator
Pilot Study of Intervention to Reduce Sunburns in Melanoma Survivors
Role: collaborator
The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma
Role: collaborator
PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy
Role: collaborator
Stage IV Surgery Versus Best Medical Therapy
Role: collaborator
All 10 trials loaded